Switch theme
Sign up to access all valuation multiples
Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Its lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Its first product, VYZULTA in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE in allergic conjunctivitis, licensed in multiple geographies.
1996
28
LTM Revenue $7.3M
Last FY EBITDA -$23.1M
$26.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nicox has a last 12-month revenue (LTM) of $7.3M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Nicox achieved revenue of $8.8M and an EBITDA of -$23.1M.
Nicox expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nicox valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $7.3M | XXX | $8.8M | XXX | XXX | XXX |
| Gross Profit | $7.3M | XXX | $7.6M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 86% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$23.1M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -262% | XXX | XXX | XXX |
| EBIT | -$12.5M | XXX | -$10.9M | XXX | XXX | XXX |
| EBIT Margin | -173% | XXX | -124% | XXX | XXX | XXX |
| Net Profit | -$20.8M | XXX | -$25.1M | XXX | XXX | XXX |
| Net Margin | -286% | XXX | -285% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $5.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Nicox's stock price is EUR 0 (or $0).
Nicox has current market cap of EUR 16.3M (or $18.3M), and EV of EUR 23.5M (or $26.4M).
See Nicox trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $26.4M | $18.3M | XXX | XXX | XXX | XXX | $-0.32 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Nicox has market cap of $18.3M and EV of $26.4M.
Nicox's trades at 3.0x EV/Revenue multiple, and -1.1x EV/EBITDA.
Equity research analysts estimate Nicox's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Nicox has a P/E ratio of -0.9x.
See valuation multiples for Nicox and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $18.3M | XXX | $18.3M | XXX | XXX | XXX |
| EV (current) | $26.4M | XXX | $26.4M | XXX | XXX | XXX |
| EV/Revenue | 3.6x | XXX | 3.0x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -1.1x | XXX | XXX | XXX |
| EV/EBIT | -2.1x | XXX | -2.4x | XXX | XXX | XXX |
| EV/Gross Profit | 3.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.9x | XXX | -0.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -1.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNicox's last 12 month revenue growth is -73%
Nicox's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.7M for the same period.
Nicox's rule of 40 is -320% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Nicox's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Nicox and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -73% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -262% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -320% | XXX | -334% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 76% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 210% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nicox acquired XXX companies to date.
Last acquisition by Nicox was XXXXXXXX, XXXXX XXXXX XXXXXX . Nicox acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Nicox founded? | Nicox was founded in 1996. |
| Where is Nicox headquartered? | Nicox is headquartered in France. |
| How many employees does Nicox have? | As of today, Nicox has 28 employees. |
| Is Nicox publicy listed? | Yes, Nicox is a public company listed on PAR. |
| What is the stock symbol of Nicox? | Nicox trades under ALCOX ticker. |
| When did Nicox go public? | Nicox went public in 1999. |
| Who are competitors of Nicox? | Similar companies to Nicox include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Nicox? | Nicox's current market cap is $18.3M |
| What is the current revenue of Nicox? | Nicox's last 12 months revenue is $7.3M. |
| What is the current revenue growth of Nicox? | Nicox revenue growth (NTM/LTM) is -73%. |
| What is the current EV/Revenue multiple of Nicox? | Current revenue multiple of Nicox is 3.6x. |
| Is Nicox profitable? | Yes, Nicox is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
